ArticleLangenbeck's archives of surgery2026
Effect of multimodal therapy in the treatment of adenocarcinoma of the esophagus and gastroesophageal junction : a population-based analysis from the German Clinical Cancer Registry Group.
Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMultimodal treatment regimes combining surgery with perioperative chemotherapy and/or preoperative radiochemotherapy have become common treatment-modalities in resectable esophageal adenocarcinoma with controversial effects on oncological outcome.
methodsThis population-based analysis was derived from 24 German cancer registries from 2000 to 2018. The overall survival was compared over three time periods, 2000-2006: pre-neoadjuvant era (PRE-NEO); 2007-2012: implementation of neoadjuvant treatment (NEO); 2013-2018: neoadjuvant/multimodal treatment strategies (POST-NEO).
resultsFor patients with adenocarcinoma of the esophagus (EAC) and gastroesophageal junction (GEJ), cTNM staging was documented in 9738 patients: Stage I (n=1405 (14%)), Stage II (n=1360 (14%)); Stage III (n=2680 (28%)); Stage IV (n=4293 (44%). The overall survival improved steadily over time for GEJ and EAC. Patients with Stage IV disease decreased over time in both tumor locations (GEJ: 71% PRENEO; 40% POST-NEO; EAC: 48% PRE-NEO to 34 %POST-NEO. Curative intended therapy increased over time (GEJ: 23% PRE-NEO; 50% POST-NEO; EAC: 29% PRENEO to 52% POST-NEO). In cTNM Stage II, perioperative chemotherapy and neoadjuvant radio chemotherapy followed by surgery were associated with longer overall survival in GEJ but not EAC compared to surgery alone. In Stage III, both multimodal treatment approaches were associated with longer overall survival in both EAC and GEJ patients when compared to surgery alone. Despite an obvious trend toward perioperative therapy, there was no statistical superiority between perioperative chemotherapy or neoadjuvant radiochemotherapy.
conclusionMultimodal therapy was independently associated with improved overall survival, particularly in patients with cTNM Stage III disease and Stage II GEJ tumors. These findings support current guideline-based treatment strategies and underscore the relevance of multimodal care in appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.